Intervju med Dr James Garner, VD Kazia Therapeutics
-
Pressmeddelanden 15 augusti, 2022Vivesto rapporterar att Apealea® lanserats i Tyskland av Inceptua
-
Regulatoriska pressmedddelanden 21 juli, 2022Vivesto utser Christer Nordstedt till tillförordnad VD
-
Regulatoriska pressmedddelanden 5 juli, 2022Vivesto har beslutat att avveckla sin verksamhet i Ryssland
Vivesto publicerade sin Q1 2022-rapport den 25 maj 2022, klockan 08.00 CET.
Oasmia förvärvar globala rättigheter för utveckling och kommersialisering av Cantrixil – ett kliniskt program inom äggstockscancer
For #investors and #media:
Today Inceptua launched Apealea® in Germany. This is great news for patients but also for Vivesto’s business as we are eligible for royalties on any sales.
#oncology #biotech
Vivesto notes the launch of Apealea® in Germany by Inceptua - Vivesto
Solna, Sweden, 15 August 2022 – Vivesto AB, an oncology-focused specialty pharmaceutical company, is pleased to note...
www.vivesto.com
This #MensHealthWeek have a look at this campaign by @menshealthforum all about how to carry out a MAN-MOT. Your car gets one regularly so why not all men? This article shows how to do your own and help early diagnosis of Prostate cancer.
Read more here:
DIY Man MOT
Your car gets one regularly but what about you? No, not a parking ticket, an MOT. Giving your body a once-over...
bit.ly